Drug Trial Radar · NCT05276297
A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy
Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
174
Actual
Start
Mar 22, 2022
Primary completion
Aug 5, 2025
Study completion Aug 5, 2025
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Mar 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety, efficacy and immune response following the sequential treatment of GlaxoSmithKline's (GSK) ASO compound (GSK3228836) and CHB-TI (GSK3528869A) in participants 18 to 65 years stable on NA treatment for CHB. The aim is to quantify the efficacy of sequential therapy as well as to determine an added value of sequential therapy over GSK3228836 therapy in CHB patients treated with NAs. In addition, the study will assess the effect of different treatment durations of GSK3228836 (12 or 24 weeks) prior to initiating GSK3528869A treatment.
Conditions
- Hepatitis B, Chronic
Interventions
GSK3228836Drug
2 doses of GSK3228836 study intervention administered subcutaneously once per week for 12 weeks (Day 1 up to Day 78) to participants in ASO12-TI and ASO12 groups, or for 24 weeks (Day 1 up to Day 162) to participants in ASO24-TI and ASO24 groups, plus loading doses administered at Day 4 and Day 11 (2 doses each day) to participants in all groups during Treatment 1 period.
GSK3528869ABiological
The GSK3528869A chronic Hepatitis B targeted immunotherapy (CHB-TI) consisting of 4 doses administered intramuscularly as follows: * 1 dose of the Chimpanzee adenovectored HBV vaccine (ChAd155-hIi-HBV) at Day 1 of Treatment 2 period. * 1 dose of the Modified Vaccinia Virus Ankara HBV vaccine (MVA-HBV) at Day 57 of Treatment 2 period. * 2 subsequent doses of the AS01B-4-adjuvanted HBc-HBs proteins (HBc-HBs/AS01B-4) administered at Day 113 and Day 169 of Treatment 2 period.
ControlDrug
4 doses of non-active control administered intramuscularly in the deltoid region of the non-dominant arm at Days 1, 57, 113 and 169 to participants in ASO24 and ASO12 control groups during Treatment 2 period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants reporting any grade 3 adverse event (AE) from first dose of GSK3228836 up to study endTime frame: From first dose of GSK3228836 (Treatment 1 -Day 1) up to study end (Treatment 2-Day 505/Day 673/Day 841)
- Percentage of participants reporting any serious adverse event (SAE) from first dose of GSK3228836 up to study endTime frame: From first dose of GSK3228836 (Treatment 1-Day 1) up to study end (Treatment 2-Day 505/Day 673/Day 841)
- Percentage of participants reporting any adverse events of special interest (AESIs) grade 3 or higher from first dose of GSK3228836 up to study endTime frame: From first dose of GSK3228836 (Treatment 1-Day 1) up to study end (Treatment 2-Day 505/Day 673/Day 841)
- Percentage of participants who achieve sustained virologic response (SVR) for 24 weeks after the planned end of active treatment in the absence of rescue medication, and difference between treatment arms (corresponding to GSK3228836 regimens)Time frame: For up to 24 weeks after the planned end of active treatment (planned end of active treatment = Treatment 1-Day 78 for ASO12 group, Treatment 1-Day 162 for ASO24 group and Treatment 2-Day 169 for ASO12-TI and ASO24-TI groups)
Locations
51 sites in 15 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Edegem, Belgium
GSK Investigational Site
Sliven, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Veliko Tarnovo, Bulgaria
GSK Investigational Site
Vratsa, Bulgaria
GSK Investigational Site
Clichy, France
GSK Investigational Site
Créteil, France
GSK Investigational Site
Lyon, France
GSK Investigational Site
Strasbourg, France
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Frankfurt, Germany
GSK Investigational Site
Leipzig, Germany
GSK Investigational Site
Pokfulam, Hong Kong
GSK Investigational Site
Bergamo, Italy
GSK Investigational Site
Milan, Italy
GSK Investigational Site
Milan, Italy
GSK Investigational Site
Roma, Italy
GSK Investigational Site
Rozzano MI, Italy
GSK Investigational Site
Makati City, Philippines
GSK Investigational Site
Pasig, Philippines
GSK Investigational Site
Krakow, Poland
GSK Investigational Site
Łańcut, Poland
GSK Investigational Site
Mysłowice, Poland
GSK Investigational Site
Cluj-Napoca, Romania
GSK Investigational Site
Craiova Dolj, Romania
GSK Investigational Site
Singapore, Singapore
GSK Investigational Site
Singapore, Singapore
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Santander, Spain
GSK Investigational Site
Seville, Spain
GSK Investigational Site
Vigo, Spain
GSK Investigational Site
Chiayi City, Taiwan
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.